Chamber, Drugmakers Back AbbVie In $448M FTC Fine Appeal

Law360 (June 13, 2019, 9:08 PM EDT) -- Drugmakers and the U.S. Chamber of Commerce urged the Third Circuit on Wednesday to overturn a ruling that slammed AndroGel maker AbbVie with $448 million in penalties for bringing “sham” patent suits to slow down generic competitors, arguing that the Pennsylvania federal judge on the case made it harder to file legitimate patent defenses.

In three amicus briefs, Amgen Inc., the U.S. Chamber of Commerce and the Pharmaceutical Research and Manufacturers of America argued that the Federal Trade Commission’s case against AbbVie Inc. made it too easy to label drug patent defense cases “baseless” or “sham” litigation for anti-competitive purposes, especially...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS